All Stories

  1. Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies

    Article • Future Oncology, June 2018, Future Medicine

    Dr Federico Cappuzzo

  2. Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

    Article • The Application of Clinical Genetics, July 2017, Dove Medical Press

    Dr Federico Cappuzzo

  3. Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series

    Article • Clinical Lung Cancer, November 2014, Elsevier

    Dr Federico Cappuzzo

  4. ALK Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

    Article • Archives of Pathology & Laboratory Medicine, November 2014, Archives of Pathology and Laboratory Medicine

    Dr Federico Cappuzzo

  5. Management of NSCLC: focus on crizotinib

    Article • Expert Opinion on Pharmacotherapy, October 2014, Informa Healthcare

    Dr Federico Cappuzzo

  6. Pharmacotherapy targeting the EGFR oncogene in NSCLC

    Article • Expert Opinion on Pharmacotherapy, September 2014, Informa Healthcare

    Dr Federico Cappuzzo

  7. Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

    Article • Clinical Lung Cancer, September 2014, Elsevier

    Dr Federico Cappuzzo

  8. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Article • The Lancet, August 2014, Elsevier

    Dr Federico Cappuzzo

  9. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

    Article • Lung Cancer Targets and Therapy, August 2014, Taylor & Francis

    Dr Federico Cappuzzo

  10. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

    Article • Journal of Cancer Research and Clinical Oncology, June 2014, Springer Science + Business Media

    Dr Federico Cappuzzo

  11. Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

    Article • Clinical Lung Cancer, May 2014, Elsevier

    Dr Federico Cappuzzo

  12. Protein kinase inhibitors to treat non-small-cell lung cancer

    Article • Expert Opinion on Pharmacotherapy, April 2014, Informa Healthcare

    Dr Federico Cappuzzo

  13. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

    Article • Nature Communications, March 2014, Springer Science + Business Media

    Dr Federico Cappuzzo

  14. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment

    Article • Cancer Cytopathology, March 2014, Wiley

    Dr Federico Cappuzzo

  15. MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

    Article • Clinical Colorectal Cancer, March 2014, Elsevier

    Dr Federico Cappuzzo

  16. A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy

    Article • The EPMA Journal, February 2014, Springer Science + Business Media

    Dr Federico Cappuzzo

  17. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

    Article • Translational Respiratory Medicine, January 2014, Springer Science + Business Media

    Dr Federico Cappuzzo

  18. Strategies for improving outcomes in NSCLC: A look to the future

    Article • Lung Cancer, December 2013, Elsevier

    Dr Federico Cappuzzo

  19. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study

    Article • Lung Cancer, November 2013, Elsevier

    Dr Federico Cappuzzo

  20. HER2 and lung cancer

    Article • Expert Review of Anticancer Therapy, October 2013, Taylor & Francis

    Dr Federico Cappuzzo

  21. Targeted therapy for NSCLC with driver mutations

    Article • Expert Opinion on Biological Therapy, August 2013, Informa Healthcare

    Dr Federico Cappuzzo

  22. MET overexpression and gene amplification in NSCLC: a clinical perspective

    Article • Lung Cancer Targets and Therapy, June 2013, Taylor & Francis

    Dr Federico Cappuzzo

  23. Rare mutations in non-small-cell lung cancer

    Article • Future Oncology, May 2013, Future Medicine

    Dr Federico Cappuzzo

  24. Erlotinib in the first-line treatment of non-small-cell lung cancer

    Article • Expert Review of Anticancer Therapy, May 2013, Taylor & Francis

    Dr Federico Cappuzzo

  25. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

    Article • Biologics Targets & Therapy, March 2013, Taylor & Francis

    Dr Federico Cappuzzo

  26. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

    Article • Current Opinion in Oncology, March 2013, Wolters Kluwer Health

    Dr Federico Cappuzzo

  27. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

    Article • Journal of Thoracic Oncology, March 2013, Elsevier

    Dr Federico Cappuzzo

  28. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Article • Nature Genetics, September 2012, Springer Science + Business Media

    Dr Federico Cappuzzo

  29. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

    Article • Clinical Cancer Research, August 2012, American Association for Cancer Research (AACR)

    Dr Federico Cappuzzo

  30. Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure

    Article • BJU International, August 2012, Wiley

    Dr Federico Cappuzzo

  31. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

    Article • Cancer Treatment Reviews, August 2012, Elsevier

    Dr Federico Cappuzzo

  32. First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: a multicenter phase II study

    Article • Journal of Cancer Research and Clinical Oncology, July 2012, Springer Science + Business Media

    Dr Federico Cappuzzo

  33. Foreword

    Article • Drugs, June 2012, Springer Science + Business Media

    Dr Federico Cappuzzo

  34. Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

    Article • Drugs, June 2012, Springer Science + Business Media

    Dr Federico Cappuzzo

  35. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

    Article • Lung Cancer, June 2012, Elsevier

    Dr Federico Cappuzzo

  36. K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

    Article • ISRN Molecular Biology, May 2012, Hindawi Publishing Corporation

    Dr Federico Cappuzzo

  37. p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer

    Article • Journal of Thoracic Oncology, March 2012, Elsevier

    Dr Federico Cappuzzo

  38. Emerging drugs for small cell lung cancer – an update

    Article • Expert Opinion on Emerging Drugs, January 2012, Informa Healthcare

    Dr Federico Cappuzzo

  39. P5-13-07: MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC).

    Article • Cancer Research, December 2011, American Association for Cancer Research (AACR)

    Dr Federico Cappuzzo

  40. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study

    Article • Journal of Clinical Pathology, November 2011, BMJ

    Dr Federico Cappuzzo

  41. Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

    Article • Journal of Clinical Oncology, October 2011, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo, Prof Mauro Magnani

  42. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer

    Article • Journal of Clinical Oncology, October 2011, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  43. PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele

    Article • European Journal of Cancer, October 2011, Elsevier

    Dr Federico Cappuzzo

  44. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

    Article • European Journal of Cancer, October 2011, Elsevier

    Dr Federico Cappuzzo

  45. Stress‐induced temperature variations in groundwater of the Monferrato area (north‐western Italy)

    Article • Geofluids, September 2011, Wiley

    Dr Federico Cappuzzo

  46. Gefitinib for non-small-cell lung cancer treatment

    Article • Expert Opinion on Drug Safety, September 2011, Informa Healthcare

    Dr Federico Cappuzzo

  47. 6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Federico Cappuzzo

  48. 6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Federico Cappuzzo

  49. 9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Federico Cappuzzo

  50. 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Federico Cappuzzo

  51. Front-line therapy in lung cancer with mutations in EGFR

    Article • Nature Reviews Clinical Oncology, August 2011, Springer Science + Business Media

    Dr Federico Cappuzzo

  52. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients

    Article • Annals of Oncology, June 2011, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  53. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

    Article • Annals of Oncology, May 2011, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  54. Abstract 3195: HMGA1 and HMGA2 over-expression in human lung carcinoma

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Federico Cappuzzo

  55. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

    Article • Lung Cancer, April 2011, Elsevier

    Dr Federico Cappuzzo

  56. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

    Article • Lung Cancer, March 2011, Elsevier

    Dr Federico Cappuzzo

  57. Is FISH floating or still swimming in the lung cancer ocean?

    Article • Annals of Oncology, February 2011, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  58. Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients

    Article • Journal of Thoracic Oncology, February 2011, Elsevier

    Dr Federico Cappuzzo

  59. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

    Article • Journal of Thoracic Oncology, October 2010, Elsevier

    Dr Federico Cappuzzo

  60. Consequences of targeted treatments for second-line therapy

    Article • Annals of Oncology, October 2010, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  61. Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens

    Article • The Oncologist, October 2010, Alphamed Press

    Dr Federico Cappuzzo

  62. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Article • The Lancet Oncology, August 2010, Elsevier

    Dr Federico Cappuzzo

  63. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

    Article • The Lancet Oncology, June 2010, Elsevier

    Dr Federico Cappuzzo

  64. Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non–small cell lung cancer: a promising feature?

    Article • Human Pathology, April 2010, Elsevier

    Dr Federico Cappuzzo

  65. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)

    Article • Lung Cancer, April 2010, Elsevier

    Dr Federico Cappuzzo

  66. Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr Federico Cappuzzo

  67. Impact of biomarkers on non-small cell lung cancer treatment

    Article • Targeted Oncology, March 2010, Springer Science + Business Media

    Dr Federico Cappuzzo

  68. Clinical implications ofMETgene copy number in lung cancer

    Article • Future Oncology, February 2010, Future Medicine

    Dr Federico Cappuzzo

  69. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

    Article • Journal of Clinical Pathology, October 2009, BMJ

    Dr Federico Cappuzzo

  70. Genetic Abnormalities of the EGFR Pathway in African American Patients With Non-Small-Cell Lung Cancer

    Article • Journal of Clinical Oncology, September 2009, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  71. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients

    Article • Annals of Oncology, September 2009, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  72. 9084 Pemetrexed vs docetaxel as second-line in NSCLC: is there a difference between adenocarcinoma and squamous cell carcinoma? – a retrospective analysis of a single institution

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Dr Federico Cappuzzo

  73. 9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Dr Federico Cappuzzo

  74. 9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Dr Federico Cappuzzo

  75. 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Dr Federico Cappuzzo

  76. 22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Dr Federico Cappuzzo

  77. Emerging drugs for small-cell lung cancer

    Article • Expert Opinion on Emerging Drugs, August 2009, Informa Healthcare

    Dr Federico Cappuzzo

  78. Gemcitabine for the treatment of advanced nonsmall cell lung cancer

    Article • OncoTargets and Therapy, August 2009, Dove Medical Press

    Dr Federico Cappuzzo

  79. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

    Article • Oncogene, August 2009, Springer Science + Business Media

    Dr Federico Cappuzzo

  80. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

    Article • Annals of Oncology, June 2009, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  81. New targeted therapies for non-small-cell lung cancer

    Article • Therapy, May 2009, Future Medicine

    Dr Federico Cappuzzo

  82. MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib

    Article • Journal of Thoracic Oncology, April 2009, Elsevier

    Dr Federico Cappuzzo

  83. Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients

    Article • Journal of Clinical Oncology, February 2009, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  84. Primary pulmonary meningioma

    Article • Lung Cancer, December 2008, Elsevier

    Dr Federico Cappuzzo

  85. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

    Article • Annals of Oncology, October 2008, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  86. Gefitinib Versus Vinorelbine in Chemotherapy-Naive Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

    Article • Journal of Clinical Oncology, September 2008, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  87. EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

    Article • Targeted Oncology, July 2008, Springer Science + Business Media

    Dr Federico Cappuzzo

  88. EGFR FISH versus mutation: Different tests, different end-points

    Article • Lung Cancer, May 2008, Elsevier

    Dr Federico Cappuzzo

  89. Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma

    Article • Cancer, March 2008, Wiley

    Dr Federico Cappuzzo

  90. Lung cancer screening with spiral CT

    Article • Lung Cancer, March 2008, Elsevier

    Dr Federico Cappuzzo, PhD Silvio Cavuto

  91. Optimizing Anti-EGFR Strategies in Cancer Treatment

    Article • Current Cancer Therapy Reviews, November 2007, Bentham Science Publishers

    Dr Federico Cappuzzo

  92. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

    Article • Annals of Oncology, October 2007, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  93. EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?

    Article • Expert Opinion on Medical Diagnostics, October 2007, Informa Healthcare

    Dr Federico Cappuzzo

  94. Assessment of tumor response in malignant pleural mesothelioma

    Article • Cancer Treatment Reviews, October 2007, Elsevier

    Dr Federico Cappuzzo

  95. 3002 ORAL Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer

    Article • European Journal of Cancer Supplements, September 2007, Elsevier

    Dr Federico Cappuzzo

  96. M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification

    Article • Journal of Thoracic Oncology, August 2007, Elsevier

    Dr Federico Cappuzzo

  97. C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)

    Article • Journal of Thoracic Oncology, August 2007, Elsevier

    Dr Federico Cappuzzo

  98. D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors

    Article • Journal of Thoracic Oncology, August 2007, Elsevier

    Dr Federico Cappuzzo

  99. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer

    Article • Annals of Oncology, July 2007, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  100. Is gemcitabine cost effective in cancer treatment?

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, June 2007, Taylor & Francis

    Dr Federico Cappuzzo

  101. Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial

    Article • Journal of Clinical Oncology, June 2007, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo, Dr. Rocco Trisolini

  102. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Article • Science, May 2007, American Association for the Advancement of Science

    Dr Federico Cappuzzo

  103. Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer

    Article • Journal of Thoracic Oncology, May 2007, Elsevier

    Dr Federico Cappuzzo

  104. EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

    Article • Journal of Thoracic Oncology, May 2007, Elsevier

    Dr Federico Cappuzzo, Dr. Rocco Trisolini

  105. Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

    Article • The Oncologist, February 2007, Alphamed Press

    Dr Federico Cappuzzo

  106. Should every lung cancer patient be tested for EGFR mutation?

    Article • Expert Opinion on Therapeutic Targets, November 2006, Informa Healthcare

    Dr Federico Cappuzzo

  107. Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria

    Article • Journal of Thoracic Oncology, November 2006, Elsevier

    Dr Federico Cappuzzo

  108. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib

    Article • Annals of Oncology, October 2006, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  109. HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer

    Article • New England Journal of Medicine, June 2006, New England Journal of Medicine (NEJM/MMS)

    Dr Federico Cappuzzo

  110. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

    Article • Annals of Oncology, June 2006, Oxford University Press (OUP)

    Dr Federico Cappuzzo, Dr. Rocco Trisolini

  111. A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

    Article • Lung Cancer, June 2006, Elsevier

    Dr Federico Cappuzzo

  112. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance

    Article • Annals of Oncology, April 2006, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  113. Clinical experience with gefitinib: An update

    Article • Critical Reviews in Oncology/Hematology, April 2006, Elsevier

    Dr Federico Cappuzzo, Dr. Rocco Trisolini

  114. Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)

    Article • Reviews on Recent Clinical Trials, January 2006, Bentham Science Publishers

    Dr Federico Cappuzzo, Dr. Rocco Trisolini

  115. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

    Article • Breast Cancer Research and Treatment, November 2005, Springer Science + Business Media

    Dr Federico Cappuzzo, Fabio Puglisi

  116. O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment

    Article • Lung Cancer, July 2005, Elsevier

    Dr Federico Cappuzzo

  117. O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib

    Article • Lung Cancer, July 2005, Elsevier

    Dr Federico Cappuzzo

  118. Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?

    Article • JNCI Journal of the National Cancer Institute, June 2005, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  119. Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients

    Article • Journal of Clinical Oncology, June 2005, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  120. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer

    Article • JNCI Journal of the National Cancer Institute, May 2005, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  121. RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer

    Article • JNCI Journal of the National Cancer Institute, March 2005, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  122. Role of gemcitabine in cancer therapy

    Article • Future Oncology, February 2005, Informa Healthcare

    Dr Federico Cappuzzo

  123. RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer

    Article • JNCI Journal of the National Cancer Institute, November 2004, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  124. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer

    Article • JNCI Journal of the National Cancer Institute, August 2004, Oxford University Press (OUP)

    Dr Federico Cappuzzo

  125. In Reply:

    Article • Journal of Clinical Oncology, April 2004, American Society of Clinical Oncology (ASCO)

    Dr Federico Cappuzzo

  126. Phase II study of gemcitabine–cisplatin–paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer

    Article • Lung Cancer, December 2003, Elsevier

    Dr Federico Cappuzzo

  127. 787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Dr Federico Cappuzzo

  128. 793 Multicenter phase II study of gemcitabine-oxaliplatin (GEMOX) chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Dr Federico Cappuzzo

  129. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

    Article • Lung Cancer, August 2003, Elsevier

    Dr Federico Cappuzzo

  130. O-143 Gemcitabine-oxaliplatin (GEMOX) chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II study

    Article • Lung Cancer, August 2003, Elsevier

    Dr Federico Cappuzzo

  131. P-362 Role of mitogen-activated protein kinase (MAPK) and AKT as predictive factors for response to ZD 1839 therapy in non-small cell lung cancer (NSCLC) patients

    Article • Lung Cancer, August 2003, Elsevier

    Dr Federico Cappuzzo

  132. P-632 Role of ZD 1839 in patients affected by metastatic NSCLC

    Article • Lung Cancer, August 2003, Elsevier

    Dr Federico Cappuzzo

  133. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma

    Article • Cancer, May 2003, Wiley

    Dr Federico Cappuzzo

  134. Emerging drugs for non-small cell lung cancer

    Article • Expert Opinion on Emerging Drugs, May 2003, Informa Healthcare

    Dr Federico Cappuzzo

  135. Small Cell Lung Cancer

    Article • January 2003, Springer Science + Business Media

    Dr Federico Cappuzzo

  136. Gemcitabine in non-small cell lung cancer

    Article • Expert Opinion on Pharmacotherapy, June 2002, Informa Healthcare

    Dr Federico Cappuzzo

  137. Present and future treatment of advanced non–small cell lung cancer

    Article • Seminars in Oncology, June 2002, Elsevier

    Dr Federico Cappuzzo

  138. Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings

    Article • Lung Cancer, December 2001, Elsevier

    Dr Federico Cappuzzo

  139. Rôle de la gemcitabine dans la chimiothérapie des stades avancés du cancer bronchique non à petites cellules: revue des principales études de phase II et III

    Article • Anti-Cancer Drugs, July 2001, Wolters Kluwer Health

    Dr Federico Cappuzzo

  140. Gemcitabine—Cisplatin chemotherapy followed by radiotherapy in locally advanced non-small cell lung cancer (nsclc): A phase II retrospective analysis

    Article • Lung Cancer, September 2000, Elsevier

    Dr Federico Cappuzzo

  141. Induction treatments in marginally operable non-small cell lung cancer

    Article • European Journal of Cancer, September 1999, Elsevier

    Dr Federico Cappuzzo

  142. Are the patients with metastatic non-small cell lung cancer curable?

    Article • Lung Cancer, September 1999, Elsevier

    Dr Federico Cappuzzo

  143. Adjuvant treatment of resected non-small cell lung cancer

    Article • Lung Cancer, September 1999, Elsevier

    Dr Federico Cappuzzo

  144. Expression of estrogen and progesterone receptors in breast metastases from malignant melanoma

    Article • European Journal of Cancer, September 1999, Elsevier

    Dr Federico Cappuzzo

  145. P9 Metastatic melanoma clinically simulating primary breast carcinoma

    Article • Melanoma Research, June 1999, Wolters Kluwer Health

    Dr Federico Cappuzzo

  146. Small-Cell Lung Cancer

    Article • January 1999, Springer Science + Business Media

    Dr Federico Cappuzzo

  147. Should all Stage IV Non-Small Cell Lung Cancer Be Treated Palliatively?

    Article • January 1999, Springer Science + Business Media

    Dr Federico Cappuzzo

  148. Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study

    Article • Nutrition, July 1997, Elsevier

    Dr Federico Cappuzzo

  149. O.26 Glutamine (GLN) supplementation in cancer patients receiving chemotherapy: a double blind randomized study

    Article • Clinical Nutrition, August 1996, Elsevier

    Dr Federico Cappuzzo

  150. 376 Oral doxifluridine plus leucovorin in elderly patients with advanced breast cancer

    Article • European Journal of Cancer, November 1995, Elsevier

    Dr Federico Cappuzzo

  151. Activity of Formestane in de novo Tamoxifen–Resistant Patients with Metastatic Breast Cancer

    Article • Oncology, January 1995, Karger Publishers

    Dr Federico Cappuzzo